Singapore markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.74-0.69 (-6.06%)
As of 02:16PM EST. Market open.
Sign in to post a message.
  • H
    Henry707
    About to get into the gap. Tha next resistance would be the 200-day moving average just below $15 in the gap. Then, it's onto $20 to fill the gap.
  • A
    Ape Vladimir
    $11.50 target by EOW $22.00 by EOY. Follow the trend and make $$$$$.
    Good company.
  • E
    End2War
    Someone slowly selling MCRB back down, in what might be thought of as "sell the news". It could be a short seller or a profit taker or a market maker fishing for stock, who knows, LOL. But, there is no denying that yesterday sparked a high volume rally, and somebody liked what they saw! So, when they get done selling, whoever is doing it, I wonder if we will see a resurgence of the demand that existed yesterday?? Won't it look like a good buying opportunity for those that liked yesterday's reports? Is this, just another time when the market offers cheap stock, or was yesterday's rally a one day fluke that had no real basis?

    MCRB does have a nice partnership with Nestle, and it is funding their work, for now. MCRB did make a new partnership with a manufacturing entitly which could be mutually beneficial. These parthernerships do show endorsements of MCRBs technology and management.

    Then their was a very good PH3 test which did meet its endpoint, and appears to be quite useful for rCDI cases, with a nearby opportunity for FDA approval, and it appears safe. More safety work is being done with the OL trial, and they are doing more efficacy testing at the same time. Normally, this would be seen as favorable.

    The problem here is that MCRB is exploring a pretty new form of medical drug, which does not yet have any (to my knowledge) FDA approvals, and some ligitimately may want to wait to see if they can get an approval before jumping in; moreover, they did run a failed effort on an earlier drug that was a surprise. But, given the PH3 trial met its endpoint, the odds of another surprise seem low.

    Personally, I think their work on the microbiome makes a lot of sense and they hold a very strong place in this new field. I like that they have a second generation drug (SER-301) working on the problem of Ulcerative Colitis, and I think they are heading for eventual success. The management team seems well equipped to get this right and their work so far is impressive, IMO.

    It is hard to see why yesterdays surge is now retracing 100%, but it could be a very good time to be a buyer. We already know their is demand for their stock, even if it is not strong today. GLTy and please do your own research and DD, and don't rely on posters.
  • j
    james
    Stock now trading above the Nasdaq biotech index and above both the 20 and 50 day moving averages on heavy volume. Something clearly in the works
  • E
    End2War
    Technically, it seems that $8 represents resistance for MCRB, and it looks like once it gets through that, it could possibly make a new move to $10. The PPS seems depressed for a company that just came off a good CC with a promising P3 trial that may lead to a nearby FDA approval. GLTY and please do your own research without relying on posters.
  • j
    josh
    (MCRB) reported a Q3 net income of $0.72 per share, reversing a loss of $0.36 per share a year ago.

    Analysts polled by Capital IQ expected a loss of $0.03 per share.

    Revenue totaled $126.7 million, up on the year from $1.4 million. Analysts expected $9.9 million, if comparable.

    Separately, Seres said it partnered with Bacthera, a contract development and manufacturing organization, to manufacture SER-109, Seres' lead product candidate for recurrent Clostridioides difficile infection, a microbial infection that causes severe diarrhea and colitis, an inflammation of the colon. Under the partnership, Bacthera will build a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site on Lonza's Ibex campus in Visp, Switzerland.
  • T
    Tesla $612
    We will visit 9 today.
    Trend is your best friend.
    Covered my short $tsla, Tesla is way over valued still.
    $BYD is truly an EV play, yet very little attention the stock get.
    Took some profit $rivn
    all in $mcrb "Dirt is good"
  • H
    Henry707
    MCRB is looking so strong. Every time they tried to bring down the stock, it's net with buyers. It broke resistance at $8, $8.50 and now $9. I got a feeling MCRB is ready to go parabolic next week. I think there will be an event next week that will make that happen. It could be a buy out offer or positive news about their BLA filing with the FDA. This is all speculation on my part. Trade at your own risk.
  • T
    Tesla $612
    600 million dollar cash on hand.
    0.72 earnings per share.
    Partnership with nestle.
    30% is nothing The real run will start soon.
  • H
    Henry707
    Technical speaking there is a huge gap between $10,90 and $20. If MCRB can move up into the gap, there is no resistance until the stock price reaches $20. The risk reward ratio is pretty good here.

    Today the stock is washing out the traders from yesterday and it may go down more and try to fill the gap from yesterday but the stock is looking like a pretty good risk here intermediate term.

    I am in at average price of $7,70 - already down over $4k... lol. But holding for at least $20/share.
  • M
    Mike T
    It seems hospitals will ordered a lot for storage in order to have enough to provide for patients. It's not similar to doctor prescriptions from a doctor's office. jmho.
  • M
    Mohamed
    Looks like cup and handle are coming on 6 months period, what do you think guys??
  • B
    Bill Hilly
    If this doesn't go up today, then Wall St has an issue with the management and doesn't trust them.
  • S
    Szabo
    Save lives. Lets go 15 than 20.
  • S
    Stock
    10$+ Coming MCRB Watch for a breakout above 9$ Huge Earnings Beat
  • w
    what
    $MCRB BOOM TOLD YA NHOD 9.20 NEXT $10.42

    BREAKING OUT ON EARNINGS & PARTNERSHIP

    SHORT SQUEEZE COMING @ 9.50 LOOK OUT SHORTS READ CHART

    HERE COMES THE SQUEEZE
  • T
    Tesla $612
    Are we going back to $50?
  • H
    Henry707
    Everyone who bought on Wednesday are/were underwater. A lot of the short term traders took losses and sold which accelerated the downward slide - causing an oversold condition in MCRB.

    Looks like today is the reversal day. Expect traders who shorted MCRB on Wednesday through today to start covering next week, which should should give MCRB a nice move to the upside.

    This is only my own speculation. Trade at your own risk. GLTA!
  • H
    Henry707
    Wow! What a nice day. BTW, there was a block of trade for 247,838 shares at the asking price of $8.18. Someone bought a lot of shares, in addition to that block, just before the close. This bodes well for this stock near term.
  • A
    Anonymous
    Big positive-- no wonder MCRB has been acting better lately-- both ARK and RA Cap have sold out of their MCRB position. Selling pressure over.